Sunday, November 27th | 3 Kislev 5783

August 31, 2017 11:45 am

New Israeli Device for Treatment of Heart Failure Successfully Implanted in Patient

avatar by

At Haifa’s Rambam Health Care Campus, the first successful implantation of the new Israeli-developed “CORolla” device for the treatment of diastolic heart failure. Photo: GPO. – Haifa’s Rambam Health Care Campus is the first medical institution in the world to successfully implant the new Israeli-developed “CORolla” device for the treatment of diastolic heart failure.

Medical professionals implanted the device in 72-year-old patient Robert MacLachlan, who had run out of treatment options for heart failure in his home country of Canada.

CORolla is an elastic device developed by the Israeli start-up CorAssist. It is implanted in the left ventricle of a beating heart using a minimally invasive procedure.

The device, invented by Rambam’s Dr. Yair Feld together with partners Dr. Yotam Reisner and Dr. Shay Dubi, improves heart function by placing pressure on the ventricle and helping fill the heart with blood.

Related coverage

November 26, 2022 10:07 am

Police on High Alert After Jerusalem Terror Bombings

i24 News - Israel's police on Friday said that it would continue to reinforce stations in Jerusalem following a bombing...

“Patients turn to us for the ‘Rambam advantage,’” said Prof. Rafi Beyer, director and CEO of Rambam. “They know that Rambam’s physician researchers have access to some of the most innovative technologies and treatments.”

“I am proud that Rambam offers treatments to patients not available anywhere else in the world,” he said.

The Israeli Health Ministry has authorized up to 10 clinical trials of the device at Rambam to test the effectiveness of the new treatment.

Forty-percent of patients diagnosed with heart failure die within five years. The new cutting-edge Israeli-developed device stands to benefit 23 million people worldwide who suffer from the disease.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.